These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 34185336)

  • 1. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
    Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
    Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
    Morawska M
    Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study.
    Hillyer A; Quint A; Ghassemian A; Joh-Carnella N; Knauer MJ; Dawd D; Lazo-Langner A; Mangel J; Lam S; Abdoh H; Xenocostas A; Deotare U; Saini L; Foster C; Louzada M; Ho J; Chin-Yee I; Phua CW
    Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):305-315. PubMed ID: 38336492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients.
    Haskin O; Ashkenazi-Hoffnung L; Ziv N; Borovitz Y; Dagan A; Levi S; Koren G; Hamdani G; Levi-Erez D; Landau D; Alfandary H
    Transplantation; 2021 Nov; 105(11):e226-e233. PubMed ID: 34381004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination.
    Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O;
    Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
    Malard F; Gaugler B; Gozlan J; Bouquet L; Fofana D; Siblany L; Eshagh D; Adotevi O; Laheurte C; Ricard L; Dulery R; Stocker N; van de Wyngaert Z; Genthon A; Banet A; Memoli M; Ikhlef S; Sestilli S; Vekhof A; Brissot E; Marjanovic Z; Chantran Y; Cuervo N; Ballot E; Morand-Joubert L; Mohty M
    Blood Cancer J; 2021 Aug; 11(8):142. PubMed ID: 34376633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P
    J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
    Gurion R; Rozovski U; Itchaki G; Gafter-Gvili A; Leibovitch C; Raanani P; Ben-Zvi H; Szwarcwort M; Taylor-Abigadol M; Dann EJ; Horesh N; Inbar T; Tzoran I; Lavi N; Fineman R; Ringelstein-Harlev S; Horowitz NA
    Haematologica; 2022 Mar; 107(3):715-720. PubMed ID: 34320790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
    Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
    Front Immunol; 2021; 12():752233. PubMed ID: 34899701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.
    Noori M; Azizi S; Abbasi Varaki F; Nejadghaderi SA; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109046. PubMed ID: 35843148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients.
    Saiag E; Grupper A; Avivi I; Elkayam O; Ram R; Herishanu Y; Cohen Y; Perry C; Furer V; Katchman H; Rabinowich L; Ben-Yehoyada M; Halperin T; Baruch R; Goldshmidt H; Hagin D; Ben-Ami R; Sprecher E; Bomze D
    Clin Microbiol Infect; 2022 May; 28(5):735.e5-735.e8. PubMed ID: 35183747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccines for patients with haematological conditions.
    Sun C; Pleyer C; Wiestner A
    Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
    [No Abstract]   [Full Text] [Related]  

  • 18. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.
    Pimpinelli F; Marchesi F; Piaggio G; Giannarelli D; Papa E; Falcucci P; Pontone M; Di Martino S; Laquintana V; La Malfa A; Di Domenico EG; Di Bella O; Falzone G; Ensoli F; Vujovic B; Morrone A; Ciliberto G; Mengarelli A
    J Hematol Oncol; 2021 May; 14(1):81. PubMed ID: 34001183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
    Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
    Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
    Parry H; McIlroy G; Bruton R; Ali M; Stephens C; Damery S; Otter A; McSkeane T; Rolfe H; Faustini S; Wall N; Hillmen P; Pratt G; Paneesha S; Zuo J; Richter A; Moss P
    Blood Cancer J; 2021 Jul; 11(7):136. PubMed ID: 34330895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.